142 related articles for article (PubMed ID: 21128554)
1. 18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours.
De Maeseneer DJ; Lambert B; Surmont V; Geboes K; Rottey SW
Acta Clin Belg; 2010; 65(5):291-9. PubMed ID: 21128554
[TBL] [Abstract][Full Text] [Related]
2. [18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
Vilstrup MH; Torigian DA
PET Clin; 2014 Oct; 9(4):391-420, v. PubMed ID: 26050944
[TBL] [Abstract][Full Text] [Related]
3. It's About Quality, Not Quantity: Qualitative FDG PET/CT Criteria for Therapy Response Assessment in Clinical Practice.
Banks KP; Peacock JG; Gusman M; Clemenshaw MN
AJR Am J Roentgenol; 2020 Aug; 215(2):313-324. PubMed ID: 32551905
[No Abstract] [Full Text] [Related]
4. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
Kostakoglu L; Goldsmith SJ
J Nucl Med; 2003 Feb; 44(2):224-39. PubMed ID: 12571214
[TBL] [Abstract][Full Text] [Related]
5. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
[TBL] [Abstract][Full Text] [Related]
6. Measuring response with FDG-PET: methodological aspects.
Allen-Auerbach M; Weber WA
Oncologist; 2009 Apr; 14(4):369-77. PubMed ID: 19357228
[TBL] [Abstract][Full Text] [Related]
7. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK
Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977
[TBL] [Abstract][Full Text] [Related]
8. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.
Kostakoglu L; Goldsmith SJ
J Nucl Med; 2004 Jan; 45(1):56-68. PubMed ID: 14734674
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effective PET investigations in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
[TBL] [Abstract][Full Text] [Related]
10. [The role of diagnostic PET in treatment planning before tumor surgery].
Haberkorn U
Chirurg; 2001 Sep; 72(9):1010-9. PubMed ID: 11594269
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
12. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.
Hicks RJ
J Nucl Med; 2009 May; 50 Suppl 1():31S-42S. PubMed ID: 19380411
[TBL] [Abstract][Full Text] [Related]
13. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Ichiya Y; Kuwabara Y; Otsuka M; Tahara T; Yoshikai T; Fukumura T; Jingu K; Masuda K
J Nucl Med; 1991 Sep; 32(9):1655-60. PubMed ID: 1880564
[TBL] [Abstract][Full Text] [Related]
14. Clinical applications of PET in oncology.
Rohren EM; Turkington TG; Coleman RE
Radiology; 2004 May; 231(2):305-32. PubMed ID: 15044750
[TBL] [Abstract][Full Text] [Related]
15. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
[TBL] [Abstract][Full Text] [Related]
16. Benefits of positron emission tomography scans for the evaluation of radiotherapy.
Decazes P; Thureau S; Modzelewski R; Damilleville-Martin M; Bohn P; Vera P
Cancer Radiother; 2020 Aug; 24(5):388-397. PubMed ID: 32448741
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of (18)F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment.
Aukema TS; Valdés Olmos RA; Klomp HM; Teertstra HJ; Belderbos JS; Vogel WV; Baas P; Burgers SA; van den Heuvel MM
J Thorac Oncol; 2009 Oct; 4(10):1226-30. PubMed ID: 19687763
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma.
Stokkel MP; Draisma A; Pauwels EK
J Cancer Res Clin Oncol; 2001 May; 127(5):278-85. PubMed ID: 11355142
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effective PET scans in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
[TBL] [Abstract][Full Text] [Related]
20. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
Nahmias C; Hanna WT; Wahl LM; Long MJ; Hubner KF; Townsend DW
J Nucl Med; 2007 May; 48(5):744-51. PubMed ID: 17475962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
